Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6B at JPM25

Jan 13, 2025, 03:04 PM

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies, a developer of treatments for central nervous system disorders, for approximately $14.6 billion. The deal, announced at the J.P. Morgan Healthcare Conference (JPM25) in San Francisco, marks the largest public biotech acquisition in over a year. Intra-Cellular Therapies' schizophrenia drug, Caplyta, is among the assets J&J will gain through this acquisition. The transaction is set to be completed within the year, with J&J offering $132 per share, a 39% premium over Intra-Cellular's closing stock price on the previous Friday. This move is seen as a strategic fit for J&J, aiming to bolster its growth in the neurosciences sector.